Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
An uncleavable form of pro–scatter factor suppresses tumor growth and dissemination in mice
Massimiliano Mazzone, Cristina Basilico, Silvia Cavassa, Selma Pennacchietti, Mauro Risio, Luigi Naldini, Paolo M. Comoglio, Paolo Michieli
Massimiliano Mazzone, Cristina Basilico, Silvia Cavassa, Selma Pennacchietti, Mauro Risio, Luigi Naldini, Paolo M. Comoglio, Paolo Michieli
View: Text | PDF
Article Oncology

An uncleavable form of pro–scatter factor suppresses tumor growth and dissemination in mice

  • Text
  • PDF
Abstract

Scatter factor (SF), also known as hepatocyte growth factor, is ubiquitously present in the extracellular matrix of tissues in the form of an inactive precursor (pro-SF). In order to acquire biological activity, pro-SF must be cleaved by specific proteases present on the cell surface. The mature form of SF controls invasive cues in both physiological and pathological processes through activation of its receptor, the Met tyrosine kinase. By substituting a single amino acid in the proteolytic site, we engineered an unprocessable form of pro-SF (uncleavable SF). Using lentivirus vector technology, we achieved local or systemic delivery of uncleavable SF in mice. We provide evidence that (a) uncleavable SF inhibits both protease-mediated pro-SF conversion and active SF–induced Met activation; (b) local expression of uncleavable SF in tumors suppresses tumor growth, impairs tumor angiogenesis, and prevents metastatic dissemination; and (c) systemic expression of uncleavable SF dramatically inhibits the growth of transplanted tumors and abolishes the formation of spontaneous metastases without perturbing vital physiological functions. These data show that proteolytic activation of pro-SF is a limiting step in tumor progression, thus suggesting a new strategy for the treatment or prevention of the malignant conversion of neoplastic lesions.

Authors

Massimiliano Mazzone, Cristina Basilico, Silvia Cavassa, Selma Pennacchietti, Mauro Risio, Luigi Naldini, Paolo M. Comoglio, Paolo Michieli

×

Figure 7

Options: View larger image (or click on image) Download as PowerPoint
Uncleavable SF arrests the progression of established tumors. (A) Tumor ...
Uncleavable SF arrests the progression of established tumors. (A) Tumor burden analysis. Tumors of the same size (approximately 100 mm3 at day 0) were repeatedly injected with the indicated lentivirus vectors, and tumor volume was measured every 3 days. The numbers in red correspond to the days of lentivirus injection. LV, lentivirus vector. (B) Tumor weight analysis for the experiment described in A. (C) Representative images of experimental tumors. The yellow ruler indicates length in centimeters. (D) Histological analysis of pulmonary metastases on lung sections stained with hematoxylin and eosin. A representative microscopic field for each group is shown. Arrows indicate the position of the metastatic lesion. Black staining is due to India ink. Metastasis incidence is shown in parenthesis. Red scale bar: 100 μm. (E) Tumor proliferation index analysis (% Ki67-positive cells). (F) Tumor apoptotic index analysis (% TUNEL-positive cells). (G) Tumor vessel analysis using the CD31 endothelial marker. Vessel density, number of vessels/mm2. Statistical significance was calculated as for Figures 5 and 6.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts